2024 年至 2031 年分子生物學酵素、試劑盒和試劑市場（按產品、應用、最終用戶和地區劃分）

分子生物學酵素、試劑盒和試劑市場評估，2024 年至 2031 年

對增強診斷程序和個人化治療的需求不斷增長，推動了分子生物學酶、試劑盒和試劑市場的發展。據 Verified Market Research 分析師稱，分子生物學酶、試劑盒和試劑市場預計將從 2023 年的 193 億美元下降，到 2031 年預測期內達到 694 億美元的估值。

受全球闡明複雜生物過程和疾病機制的雄心推動，基因組學和蛋白​​質組學研究蓬勃發展，從而推動了對分子生物學酶、試劑盒和試劑的需求。需求激增將推動市場在 2024 年至 2031 年期間以 17.35% 的複合年增長率成長。

分子生物學酶、試劑盒和試劑市場的定義/概述

分子生物學酵素、試劑盒和試劑是用於操作和分析 DNA、RNA 和蛋白質的專門生化工具。這些工具包括酶，例如 DNA 聚合酶（可擴增 DNA）、限制性內切酶（可在特定區域切割 DNA）和連接酶（可將 DNA 片段連接在一起）。試劑盒和試劑包括執行分子生物學程序所需的組件，例如 PCR（聚合酶鍊式反應）以擴增 DNA、凝膠電泳以分離 DNA 以及定序以確定 DNA 中鹼基的順序。

此外，這些產品對於各種應用至關重要，包括基因研究、醫學診斷、法醫分析和治療開發，使科學家和臨床醫生能夠研究疾病的分子原因，識別基因突變，並允許有針對性的治療得到發展。

推動市場成長的關鍵因素有哪些？

基因組學和蛋白​​質組學研究的快速進步極大地促進了分子生物學酶、試劑盒和試劑市場的發展。定序、CRISPR 等基因編輯技術以及蛋白質體學研究的技術進步正在拓寬分子生物學酶的應用並促進市場擴張。這些突破使得人們能夠精確地識別基因變化和蛋白質，促進個人化醫療和生物技術創新的發展。

對個人化醫療日益增長的需求是市場的主要驅動力。個人化醫療利用基因和蛋白質組學數據來為特定患者制定治療方案，需要在診斷、治療標靶發現和藥物開發中使用分子生物學酶和試劑盒。這項策略提高了治療效果，同時減少了副作用，促進了分子生物學產品在醫療保健領域的應用。

此外，生物製藥產業的興起是推動分子生物學酶、試劑盒和試劑需求的主要因素。這些工具對於生物製藥（包括治療性蛋白質和核酸類產品）的研究、開發和生產至關重要。生物製藥研發支出的不斷增加以及藥物開發管道中生物製劑數量的不斷增加，推動了對高品質分子生物學產品的需求市場不斷增長。

阻礙市場成長的主要課題是什麼？

酵素、試劑盒和試劑必需品質高且可重複，以提供可靠的研究和臨床結果。然而，製造流程、原料品質和儲存條件的變化都會影響產品的一致性。由於分子生物學應用需要較高的特異性和靈敏度，其複雜性日益增加，這進一步加劇了這項課題。解決這些問題需要嚴格的品質控管程序、協議標準化和驗證流程，所有這些都會增加製造成本並限制這些關鍵儀器的可用性，從而阻礙市場需求。

監理合規是進入市場的一大障礙。用於診斷、藥物研究和治療應用的產品必須符合美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等組織制定的嚴格監管要求。獲得批准既費時又費錢，會延遲產品發佈、增加開發成本並限制市場准入。

目錄

第 1 章全球分子生物學酵素、試劑盒與試劑市場簡介

市場概況
• 研究範圍
• 先決條件

第 2 章執行摘要

第 3 章：經過驗證的市場研究方法

• 資料探勘
• 驗證
• 主要來源
• 資料來源列表

第 4 章 分子生物學酵素、試劑盒與試劑的全球市場展望

• 概述
• 市場動態
  • 驅動程式
  • 阻礙因素
  • 機會
• 波特五力模型
• 價值鏈分析

5. 全球分子生物學酵素、試劑盒與試劑市場（依應用）

• 概述
• 聚合酶鍊式反應 (PCR)
• 排序
• 克隆 表觀遺傳學
• 限制性酵素消化
• 合成生物學
• 其他

6. 全球分子生物學酵素、試劑盒和試劑市場（依產品劃分）

• 概述
• 試劑盒和試劑
• 酶
• 聚合酶
• 連接酶
• 其他

7. 全球分子生物學酵素、試劑盒和試劑市場（依最終用戶劃分）

• 概述
• 學術和研究機構
• 製藥和生技公司
• 醫院和診斷中心
• 其他

8. 全球分子生物學酵素、試劑盒和試劑市場（按地區）

• 概述
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 其他歐洲國家
  亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區
  • 拉丁美洲
  • 中東和非洲

9. 全球分子生物學酵素、試劑盒與試劑市場：競爭格局

• 概述
• 各公司的市場排名
• 主要發展策略

第十章 公司簡介

• Thermo Fisher Scientific Inc
• Illumina
• Qiagen
• Agilent Technologies
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Jena Bioscience GmbH
• Bioline Technologies
• Promega Corporation
• Rockland Immunochemicals Inc

第 11 章 重大進展

• 產品發佈/開發
• 合併和收購
• 業務擴展
• 夥伴關係和合作關係

第 12 章附錄

• 相關研究

Molecular Biology Enzymes And Kits And Reagents Market Valuation - 2024-2031

The growing demand for enhanced diagnostic procedures and personalized treatment is driving the Molecular Biology Enzymes And Kits And Reagents Market. According to the analyst from Verified Market Research, the Molecular Biology Enzymes And Kits And Reagents Market is estimated to reach a valuation of USD 69.4 Billion over the forecast period 2031, subjugating around USD 19.3 Billion in 2023.

The boom in genomic and proteomic research efforts, fueled by the global ambition to comprehend complex biological processes and disease mechanisms, is driving up demand for molecular biology enzymes, kits, and reagents. This surge in demand enables the market to grow at a CAGR of 17.35% from 2024 to 2031.

Molecular Biology Enzymes And Kits And Reagents Market: Definition/ Overview

Molecular biology enzymes, kits, and reagents are specialized biochemical instruments for manipulating and analyzing DNA, RNA, and proteins. These tools include enzymes such as DNA polymerases, which amplify DNA, restriction endonucleases, which cut DNA at specified regions, and ligases, which combine DNA fragments, among others. Kits and reagents contain the components required to perform molecular biology procedures such as PCR (polymerase chain reaction) for DNA amplification, gel electrophoresis for DNA separation, and sequencing to determine the order of DNA bases.

Furthermore, these products are essential in various applications, including genetic research, medical diagnostics, forensic analysis, and therapeutic development, allowing scientists and clinicians to investigate the molecular causes of diseases, identify genetic variations, and develop targeted treatments.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Key Drivers that Bolster the Market Growth?

Rapid advances in genomics and proteomics research have considerably boosted the molecular biology enzymes, kits, and reagents market. Technological advancements in sequencing technologies, gene editing techniques such as CRISPR, and proteomics studies have broadened the applications of molecular biology enzymes, driving market expansion. These breakthroughs allow for precise genetic changes and protein identification, promoting the development of personalized medicine and biotechnological innovations.

The growing need for personalized medication has become a key market driver. Personalized medicine uses genetic and proteomic data to personalize treatments for specific patients, necessitating the use of molecular biology enzymes and kits in diagnostics, therapeutic target discovery, and drug development. This strategy improves therapy efficacy while reducing negative effects, encouraging the use of molecular biology products in healthcare.

Furthermore, the rise of the biopharmaceutical industry is a key factor driving demand for molecular biology enzymes, kits, and reagents. These tools are required for the study, development, and manufacture of biopharmaceuticals, such as therapeutic proteins and nucleic acid-based products. The increased expenditure in biopharmaceutical R&D, together with the growing number of biologics in the drug development pipeline, boosting the expansion of the market by needing high-quality molecular biology products.

What are the Primary Challenges Hindering the Growth of the Market?

Enzymes, kits, and reagents must be of high quality and reproducible to provide trustworthy research and clinical results. However, variability in the manufacturing process, raw material quality, and storage conditions all have an impact on product consistency. This difficulty is exacerbated by the growing complexity of molecular biology applications that require high specificity and sensitivity. Addressing these concerns necessitates stringent quality control procedures, protocol standardization, and validation processes, all of which raise manufacturing costs limit the availability of these vital instruments and inhibit market expansion.

Regulatory compliance presents a substantial barrier for the market. Products used in diagnostics, medication research, and therapeutic applications must adhere to high regulatory requirements established by organizations such as the United States Food and Medication Administration (FDA) and the European Medicines Agency. Obtaining approvals is time-consuming and expensive, delaying product releases, increasing development expenses and restricting market growth.

Category-Wise Acumens

Is Kits and Reagents Segment Dominating the Product Category?

According to VMR analysis, the kits and reagents segment is estimated to hold the largest market share in the product segment during the forecast period. Kits and reagents are required for a variety of molecular biology techniques, such as PCR, sequencing, cloning, and gene expression studies. Their adaptability and integration into multiple processes make them essential for ordinary and specialized research jobs. This broad applicability drives demand in a variety of disciplines, including academic research, clinical diagnostics, drug discovery, and development, contributing to their significant market share.

Kits and reagents are intended to simplify difficult molecular biology processes, lowering the time and technical skill required to conduct research. They frequently include pre-measured components and precise protocols to reduce errors and variability, improving repeatability and efficiency in the lab. This convenience, combined with the promise of consistent results, appeals to both seasoned researchers and those new to molecular biology, increasing adoption and market dominance.

Furthermore, the expanding emphasis on genomic research, driven by efforts to understand the genetic basis of diseases and develop personalized therapy, is resulting in a major increase in demand for high-quality kits and reagents. These items are essential for analyzing genetic data, identifying biomarkers, and creating tailored medicines. The growth of personalized medicine, which uses genetic information to customize therapies to specific patients, is increasing the demand for dependable and efficient kits and reagents, reinforcing their market position.

What are the Key Driving Forces for the Dominance of the PCR Application Segment?

The polymerase chain reaction (PCR) segment is estimated to dominate the Molecular Biology Enzymes And Kits And Reagents Market during the forecast period. PCR is a fundamental technique used in genetic and molecular research, as well as diagnostic applications such as infectious disease detection, cancer research, and genetic testing. The COVID-19 pandemic highlighted the critical role of PCR in quick testing and diagnostics, resulting in an unprecedented rise in demand for PCR kits and reagents. Its versatility and capacity to quickly amplify tiny pieces of DNA or RNA make it essential in both clinical and scientific settings.

Continuous advances in PCR technologies, such as real-time PCR (qPCR) and digital PCR (dPCR), have extended applications while improving sensitivity, specificity, and throughput. These advancements have simplified the application of PCR in a variety of disciplines, including personalized medicine, where it is utilized for patient stratification and disease progression monitoring, resulting in increased demand for PCR-related products.

Furthermore, the trend to precision medicine, as well as the growing demand for genetic testing for inherited illnesses, pharmacogenomics, and disease risk assessment, has accelerated the usage of PCR. PCR's capacity to detect specific DNA sequences makes it indispensable in various applications, adding to its market dominance. The growing awareness and acceptance of personalized healthcare solutions has resulted in increased investment in R&D activities in this area, which has fueled the rise of the PCR segment.

Country/Region-wise Acumens

Will Flourishing Healthcare Industry in North America Fuel this market?

According to VMR analyst, North America is estimated to dominate the Molecular Biology Enzymes And Kits And Reagents Market during the forecast period. The United States, in particular, provides substantial public and private financing for healthcare and biological research. The National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA), as well as private organizations and pharmaceutical firms, all offer significant financing for genetics, molecular biology, and related research. This financial support is driving up demand for molecular biology goods and helps to build the market.

Furthermore, North America is home to some of the world's largest biotechnology and pharmaceutical industries, which rely heavily on molecular biology enzymes, kits, and reagents. These industries deal with drug research, development, and diagnostic test development, all of which rely significantly on molecular biology techniques. The concentration of these businesses in North America, together with their innovation capabilities and market size, fueling the demand and development of advanced molecular biology products.

What are the Factors Leading to a Significant Share in Europe?

Europe has been in the lead in implementing precision medicine efforts and large-scale genomic projects. Countries such as the United Kingdom's 100,000 Genomes Project and France's National Genomic Medicine Strategy 2025 strive to integrate genomics into their healthcare systems. These projects necessitate considerable use of molecular biology products for DNA sequencing, PCR, and other genomic technologies, resulting in market expansion in the region.

Furthermore, European countries have made considerable investments in life sciences and biotechnology research, including both public and commercial funding. Horizon Europe, is the EU's primary funding program for research and innovation, with a budget of approximately €100 billion for the years 2021-2027, demonstrating the region's commitment to advancing scientific and technical research, including molecular biology. These expenditures increase the need for molecular biology enzymes, kits, and reagents required for cutting-edge research and development operations.

Competitive Landscape

The Molecular Biology Enzymes, and Kits and Reagents Market is characterized by a dynamic competitive landscape, driven by rapid advances in biotechnology and rising demand for molecular biology applications in a variety of industries, including healthcare, research, and diagnostics. The emphasis on precision and reliability, combined with severe regulatory requirements, influences the competitive strategies of businesses in this market.

Some of the prominent players operating in the Molecular Biology Enzymes And Kits And Reagents Market include:

Thermo Fisher Scientific Inc, Illumina, Qiagen, Agilent Technologies, F. Hoffmann-La Roche Ltd., Merck KGaA, Jena Bioscience GmbH, Bioline Technologies, Promega Corporation, Rockland Immunochemicals Inc, Takara Bio Inc, New England Biolabs Inc., Lucigen Corporation, GE Healthcare, PerkinElmer Inc., Bio-Rad Laboratories, Abbott Laboratories.

Latest Developments

In February 2024, Agilent Technologies announced the release of its new SureSelectXT Target Enrichment Kit for Illumina Sequencing, a comprehensive solution for targeted next-generation sequencing (NGS) library preparation.

In February 2024, Thermo Fisher Scientific announced a collaboration with Bio-Techne to create and commercialize new companion diagnostics for targeted cancer medicines.

In January 2024, Merck KGaA expanded its CRISPR portfolio with the introduction of new Cas9 enzymes and guide RNAs for gene editing applications.

In January 2024, Illumina announced the release of their new NovaSeq X Plus sequencing device, which provides higher throughput and accuracy for whole-genome and RNA sequencing applications.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET, BY APPLICATION

• 5.1 Overview
• 5.2 Polymerase Chain Reaction (PCR)
• 5.3 Sequencing
• 5.4 Cloning
• 5.5 Epigenetics
• 5.6 Restriction Digestion
• 5.7 Synthetic Biology
• 5.8 Others

6 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET, BY PRODUCT

• 6.1 Overview
• 6.2 Kits and Reagents
• 6.3 Enzymes
• 6.4 Polymerases
• 6.5 Ligases
• 6.6 Others

7 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET, BY END-USER

• 7.1 Overview
• 7.2 Academic and Research Institutes
• 7.3 Pharmaceutical and Biotechnology Companies
• 7.4 Hospitals and Diagnostic Centers
• 7.5 Others

8 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.3 Canada
  • 8.2.4 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS AND REAGENTS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Thermo Fisher Scientific Inc
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Illumina
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Qiagen
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Agilent Technologies
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 F. Hoffmann-La Roche Ltd.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Merck KGaA
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Jena Bioscience GmbH
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Bioline Technologies
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Promega Corporation
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Rockland Immunochemicals Inc
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research